Records containing: IgA Nephropathy
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-06-04A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
-
CLINICAL_TRIALS study record update · 2026-04-21A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)
-
CLINICAL_TRIALS study record update · 2026-04-20A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
-
CLINICAL_TRIALS study record update · 2026-04-13IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
-
CLINICAL_TRIALS study record update · 2026-04-13A Phase II, Open-Label Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-04-01A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
-
CLINICAL_TRIALS study record update · 2026-04-01A Single-arm, Multicenter, Phase III Study to Assess Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients of 2 to <18 Years of Age With Primary Immunoglobulin A Nephropathy (IgAN)
-
CLINICAL_TRIALS study record update · 2026-03-23A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ARO-CFB in Adult Healthy Volunteers and Adult Patients With Complement-Mediated Kidney Disease
-
CLINICAL_TRIALS study record update · 2026-03-18China IgNITE - Umbrella Protocol: IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection
-
CLINICAL_TRIALS study record update · 2026-03-12A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Groups, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
-
CLINICAL_TRIALS study record update · 2026-03-10An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
-
CLINICAL_TRIALS study record update · 2026-02-05An Open-label Study to Assess the Efficacy and Safety of Extended TARPEYO® (Delayed-release Budesonide Capsules) Treatment in Adult Patients With Primary IgA Nephropathy Who Have Completed 9 Months of TARPEYO® 16 mg Once Daily Treatment in Real-world Clinical Practice
-
CLINICAL_TRIALS study record update · 2026-01-30A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)
-
CLINICAL_TRIALS study record update · 2026-01-22Managed Access Programs for EXV811, Atrasentan
-
CLINICAL_TRIALS study record update · 2025-12-23A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
-
CLINICAL_TRIALS study record update · 2025-12-16A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease
-
CLINICAL_TRIALS study record update · 2025-12-09A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
-
CLINICAL_TRIALS study record update · 2025-11-20Treatment of IgA Nephropathy According to Renal Lesions
-
CLINICAL_TRIALS study record update · 2025-09-30A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)
-
CLINICAL_TRIALS study record update · 2025-09-19A Phase II Clinical Study to Evaluate the Safety and Efficacy of CM313 (SC) Injection in Subjects With Primary IgA Nephropathy
-
CLINICAL_TRIALS study record update · 2025-09-15A Prospective, Single-Arm Clinical Study of Budesonide in Combination With Ambrisentan for the Treatment of Patients With IgA Nephropathy
-
CLINICAL_TRIALS study record update · 2025-08-20A Single-Center, Randomized, Open-Label, Crossover Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
-
CLINICAL_TRIALS study record update · 2025-08-11A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
-
CLINICAL_TRIALS study record update · 2025-07-14Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary IgA Nephropathy: Multi-center, Multi-arm and Multi-stage
-
CLINICAL_TRIALS study record update · 2025-06-08Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis